Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07335315 · ClinicalTrials.gov registry record
Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
A clinical trial of Pituitary Adenoma and Cushing Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 110
- Enrollment target
- 1
- Study location
NCT07335315: Recruiting study of Pituitary Adenoma and Cushing Disease, sponsored by Mayo Clinic.
NCT07335315 is a study of Pituitary Adenoma and Cushing Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 110 participants, below the 276-participant average among 9 other Pituitary Adenoma trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07335315, a study of Pituitary Adenoma and Cushing Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot and feasibility study aims to combine recent advances in ultrasound imaging, specifically an endonasal transducer array and contrast enhanced ultrasound, to offer an intraoperative image-guided solution for lesion-specific surgical resection to impact clinical outcome. Should this imaging approach help isolate specific lesions and prevent surgical resection of normal pituitary tissue in this first-in-humans study, then the results will provide clinical data for a much larger multi-center clinical trial.
Primary Outcome
Non-contrast ultrasound images will be evaluated by a board certified neuroradiologists with experience reviewing pituitary imaging. The ultrasound images will be scored on the identification, size, location, echogenicity, and enhancement of any potential pituitary lesions as well as a confidence level in identifying the adenoma (1-5 Likert scale) with 1 being non-diagnostic/poor and 5 being excellent/diagnostic quality.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Contrast enhanced pituitary magnetic resonance imaging (MRI)
- DIAGNOSTIC_TEST Contrast enhanced ultrasound
- DIAGNOSTIC_TEST Non-Contrast Ultrasound
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2027-01 |
What NCT07335315 shows while recruiting
NCT07335315 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 276-participant average among 9 other Pituitary Adenoma trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Pituitary Adenoma appearing as the primary indexed condition, and to 3 interventions - of which Contrast enhanced pituitary magnetic resonance imaging (MRI) is the first listed.
NCT07335315 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07335315 about?
NCT07335315 is a clinical study titled "Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors". This pilot and feasibility study aims to combine recent advances in ultrasound imaging, specifically an endonasal transducer array and contrast enhanced ultrasound, to offer an intraoperative image-guided solution for lesion-specific surgical resection to impact clinical outcome. Should this imaging...
What is the current status of trial NCT07335315?
This trial is currently recruiting. The enrollment target is 110 participants. The study started on 2024-06-19. Estimated completion is 2027-01.
What conditions does trial NCT07335315 study?
This clinical trial studies the following conditions: Pituitary Adenoma, Cushing Disease.
What interventions are being tested in trial NCT07335315?
The interventions under investigation include: Contrast enhanced pituitary magnetic resonance imaging (MRI) (DIAGNOSTIC_TEST), Contrast enhanced ultrasound (DIAGNOSTIC_TEST), Non-Contrast Ultrasound (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07335315?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07335315 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pituitary Adenoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07335315's enrollment target sits among peer trials
110 6th of 9 higher than 4 of 9 other Pituitary Adenoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pituitary Adenoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
RECRUITING · Phase 4
-
DDAVP for Pituitary Adenoma
RECRUITING · NA
-
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
RECRUITING · Phase 4
-
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
RECRUITING · Phase 1
-
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Surgical Debulking of Pituitary Adenomas
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI